

Senate Health and Human Services Committee

Sophie Walsh 271-3469

HB 1735-FN, permitting treatment of certain severe illness under the right to try act.

Hearing Date: April 2, 2026

Time Opened: 4:55 p.m.

Time Closed: 5:02 p.m.

Members of the Committee Present: Senators Rochefort, Avard, Birdsell, Prentiss and Long

Members of the Committee Absent: None

Bill Analysis: This bill permits treatment of certain severe illness under the right to try act.

Sponsors:

Rep. Cole

Rep. Kesselring

Rep. Layon

Rep. Notter

Rep. Reinfurt

Rep. D. McGuire

Rep. Bernardy

Rep. Ulery

Rep. Morton

Sen. Murphy

Sen. Sullivan

Sen. Innis

Who supports the bill: Rep. Robert Wherry, Rep. Yury Polozov, Rep. Linda McGrath, Liz Barbour, Gretchen Wade (Granite Bio Innovation), Raechel Lambert, Ryan Lambert, and Dan Richardson.

Who opposes the bill: Hon. Dianne Schuett, Liz-Anne Platt, Mary Danca, Dennis Jakubowski, Maura Willing, Louise Spencer, Deborah Jakubowski, Lorna Carlisle, David Tucker, William Palmer, Tami Lanzillo Zeimetz, Steven Zeimetz, and Lisa Rivard.

Who is neutral on the bill: No one.

Summary of testimony presented:

Raechel Lambert

- Ms. Lambert stated that she is speaking in support of the bill.
- Patients are already traveling abroad to receive experimental treatments. They should not have to leave the country to access these hope-providing treatments.
- This bill only covers treatments that have already passed Phase I of FDA trials, which prove safety. Furthermore, this only applies to people who have chronic disabilities or illnesses. This is an opt-in initiative including guardrails and oversight.

- Ms. Lambert referenced potential amendments to exclude foreign entities and explained that no one has any issue with keeping bad actors out, as long as we are not blocking legitimate patients and entities from innovating in the medical field.
- While Montana has expanded their regulations, founders are not eager to move there due to lacking workforce and manufacturing capabilities. New Hampshire is in a much better position, especially considering the state's proximity to Boston.

Ryan Lambert

- Mr. Lambert explained that he is currently working on a new development to enable experimental clinics and help startups bring innovative treatments to the market. Through this work, Mr. Lambert is in active conversations with companies deciding if they want to establish roots and begin operating.
- He emphasized that this is not a question of if this will work begin happening, but rather where it will happen. This bill will help ensure New Hampshire is one of those places and revitalize the economy. A small number of companies choosing to locate in New Hampshire would have an outsized impact.
- Expanded access to experimental treatments are already happening, often outside of the United States. This ensures that this is happening with oversight, regulations, and data collection.
- This bill also sends a clear signal that New Hampshire is open to innovation and willing to lead.